Can genes predict lung function loss? new study seeks answers
NCT ID NCT00373841
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is collecting blood and tissue samples from 500 people with idiopathic pulmonary fibrosis to find genetic and protein markers that might predict rapid lung function decline. Researchers will compare these markers with changes in symptoms over time. The goal is to better understand and anticipate disease progression, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict when a patient's lung function might rapidly worsen, allowing earlier intervention.
- What could go wrong
- This is an observational study, not a treatment trial. It may not identify reliable markers, and any findings would need further validation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Michelle F MacPherson
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow lung scarring in IPF?
- Beyond the lungs: the hidden emotional toll of IPF medications
- Can umbilical cord stem cells ease a scarring lung disease?
- Spotting hidden blood clots in scarred lungs: a study hunts for clues
- What makes someone stop a lung fibrosis drug? a study asks patients directly
- A smarter way to track lung disease? new platform aims to personalize COPD and IPF care